IDEXX Laboratories, Inc. (IDXX) Stake Lessened by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 468,504 shares of the company’s stock after selling 15,560 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in IDEXX Laboratories were worth $87,151,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atria Investments LLC purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth $351,000. DNB Asset Management AS purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth $4,272,000. Bank of Montreal Can lifted its stake in shares of IDEXX Laboratories by 10.4% during the 3rd quarter. Bank of Montreal Can now owns 186,115 shares of the company’s stock worth $46,466,000 after purchasing an additional 17,482 shares during the period. First Hawaiian Bank purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth $384,000. Finally, Nisa Investment Advisors LLC lifted its stake in shares of IDEXX Laboratories by 6.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 68,065 shares of the company’s stock worth $16,993,000 after purchasing an additional 3,920 shares during the period. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Shares of IDXX opened at $207.74 on Monday. The firm has a market capitalization of $17.91 billion, a P/E ratio of 48.77 and a beta of 1.02. IDEXX Laboratories, Inc. has a twelve month low of $166.70 and a twelve month high of $256.22.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Friday, February 1st. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.08. The business had revenue of $549.39 million for the quarter, compared to analyst estimates of $546.04 million. IDEXX Laboratories had a negative return on equity of 1,501.97% and a net margin of 17.03%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the company posted $0.43 EPS. As a group, analysts predict that IDEXX Laboratories, Inc. will post 4.69 earnings per share for the current fiscal year.

A number of research analysts have weighed in on IDXX shares. BidaskClub raised IDEXX Laboratories from a “sell” rating to a “hold” rating in a research note on Thursday, January 24th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 price target on the stock in a research note on Monday, February 4th. Bank of America reduced their price target on IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, November 2nd. Finally, Canaccord Genuity reduced their price target on IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Monday, November 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $246.00.

In related news, VP Giovani Twigge sold 997 shares of the stock in a transaction on Wednesday, February 6th. The stock was sold at an average price of $209.08, for a total value of $208,452.76. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Rebecca M. Henderson sold 3,504 shares of the stock in a transaction on Tuesday, November 27th. The stock was sold at an average price of $194.92, for a total value of $682,999.68. Following the completion of the transaction, the director now directly owns 22,200 shares in the company, valued at $4,327,224. The disclosure for this sale can be found here. Insiders sold a total of 20,406 shares of company stock worth $4,201,760 over the last ninety days. Corporate insiders own 2.56% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.chaffeybreeze.com/2019/02/11/idexx-laboratories-inc-idxx-stake-lessened-by-cibc-private-wealth-group-llc.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Story: How is net asset value different from market price?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply